Glaxo SmithKline EU Merger Approval Includes Potential Divestment Of Ariflo
Executive Summary
Glaxo SmithKline will be required to divest the chronic obstructive pulmonary disease therapy Ariflo in Europe if all competing agents fail in clinical trials.
You may also be interested in...
SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate
SmithKline Beecham could face competition to its antidepressant Paxil in the U.S. from an NDAed version of a different salt of paroxetine filed by Synthon.
SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate
SmithKline Beecham could face competition to its antidepressant Paxil in the U.S. from an NDAed version of a different salt of paroxetine filed by Synthon.
FTC Will Have Opportunity To Address Genomics In Review Of Glaxo/SB
The Glaxo SmithKline merger will provide an opportunity for antitrust regulators to weigh in on the commercial exploitation of the human genome.